Senti Biosciences (SNTI) Equity Average (2021 - 2025)
Senti Biosciences has reported Equity Average over the past 5 years, most recently at $6.9 million for Q4 2025.
- For Q4 2025, Equity Average fell 67.08% year-over-year to $6.9 million; the TTM value through Dec 2025 reached $6.9 million, down 67.08%, while the annual FY2025 figure was $15.6 million, 66.25% down from the prior year.
- Equity Average for Q4 2025 was $6.9 million at Senti Biosciences, down from $16.4 million in the prior quarter.
- Over five years, Equity Average peaked at $147.3 million in Q3 2022 and troughed at -$116.6 million in Q1 2022.
- A 5-year average of $28.0 million and a median of $31.3 million in 2025 define the central range for Equity Average.
- Biggest five-year swings in Equity Average: skyrocketed 546.22% in 2023 and later plummeted 72.21% in 2024.
- Year by year, Equity Average stood at -$106.4 million in 2021, then soared by 225.74% to $133.8 million in 2022, then tumbled by 44.0% to $74.9 million in 2023, then plummeted by 72.21% to $20.8 million in 2024, then tumbled by 67.08% to $6.9 million in 2025.
- Business Quant data shows Equity Average for SNTI at $6.9 million in Q4 2025, $16.4 million in Q3 2025, and $31.3 million in Q2 2025.